SHEA Pediatric Leadership Council commentary: Personal protective equipment during care of children with multisystem inflammatory syndrome in children (MIS-C)

In April 2020, amid the coronavirus disease 2019 (COVID-19) pandemic, providers in the United Kingdom described a group of pediatric hospital admissions secondary to fever and multisystem inflammation which has subsequently been described in several countries, including the United States.1–4 Since t...

Full description

Saved in:
Bibliographic Details
Published in:Infection control and hospital epidemiology 2021-09, Vol.42 (9), p.1108-1110
Main Authors: Muller, Martha L, Logan, Latania K, Kociolek, Larry K, Guzman-Cottrill, Judith A, Bartlett, Allison H, Schaffzin, Joshua K, Ravin, Karen A, Rubin, Lorry G, Lake, Jason, Caughell, Carolyn, Ramirez-Avila, Lynn
Format: Article
Language:English
Subjects:
Child
Coronaviruses
COVID-19
Disease control
Humans
Infectious diseases
Leadership
Multisystem inflammatory syndrome in children
Pandemics
Pediatrics
Personal Protective Equipment
Protective equipment
Public health
Respiratory tract
Systemic Inflammatory Response Syndrome - therapy
Teenagers
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In April 2020, amid the coronavirus disease 2019 (COVID-19) pandemic, providers in the United Kingdom described a group of pediatric hospital admissions secondary to fever and multisystem inflammation which has subsequently been described in several countries, including the United States.1–4 Since then, several countries have described an epidemiologic association of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and this clinical presentation,5 with the development of cases noted a few weeks following peaks in community COVID-19 activity.1 The condition has been named Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States and Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in Europe.5 Patients present variably along a spectrum, including fever, conjunctival injection, rash, abdominal pain, and vomiting.1,2,4 Laboratory evidence of inflammation is routinely present.1,4 The clinical presentation in patients has been similar to other pediatric inflammatory conditions, to include Kawasaki disease, toxic shock syndrome, bacterial sepsis, and macrophage activation syndrome.1,3,4,6–9 Although MIS-C has been compared to Kawasaki disease, several symptoms are more notable in MIS-C disease: presentation in older aged children, a predominance of abdominal symptoms, frequent lymphopenia, increased incidence of left ventricular systolic dysfunction, and acute heart failure.3,4,10,11 MIS-C is likely a rare complication of SARS-CoV-2 infection,1,4,12 with a reported incidence of ˜2 in 100,000 persons
ISSN:0899-823X
1559-6834
DOI:10.1017/ice.2021.242